Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis

References

• Cutting GR. MODIFIER GENETICS: cystic Fibrosis. Annu Rev Genom Hum Genet. 2005;6(1):237–260. doi:10.1146/annurev.genom.6.080604.162254
   Web of Science ®Google Scholar
• Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1(1):15010. doi:10.1038/nrdp.2015.1027189798
   PubMed Web of Science ®Google Scholar
• Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK registry data. J Cyst Fibros. 2018;17(2):218–227. doi:10.1016/j.jcf2017.11.01929311001
   PubMed Web of Science ®Google Scholar
• Nettie Burke SA. The Australian cystic fibrosis data registry annual report, 2019. Monash University, Department of Epidemiology and Preventive Medicine; 2021. Available from: https://www.cysticfibrosis.org.au/getmedia/bcab56d9-5bbe-4b19-9486-85a0ad2c2a21/ACFDR-2019-Annual-Report.pdf.aspx. Accessed June 15, 2021.
   Google Scholar
• Thabut G, Christie JD, Mal H, et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med. 2013;187(12):1335–1340. doi:10.1164/rccm.201303-0429OC23590274
   PubMed Web of Science ®Google Scholar
• Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for heart and lung transplantation: thirty-fourth adult lung and heart-lung transplantation report—2017; focus theme: allograft ischemic time. J Heart Lung Transpl. 2017;36(10):1047–1059. doi:10.1016/j.healun.2017.07.016
   PubMed Web of Science ®Google Scholar
• Benden C, Goldfarb SB, Stehlik J. An aging population of patients with cystic fibrosis undergoes lung transplantation: an analysis of the ISHLT Thoracic Transplant Registry. J Heart Lung Transpl. 2019;38(11):1162–1169. doi:10.1016/j.healun.2019.06.025
   Web of Science ®Google Scholar
• Paraskeva MA, Edwards LB, Levvey B, et al. Outcomes of adolescent recipients after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transpl. 2018;37(3):323–331. doi:10.1016/j.healun.2017.02.017
   PubMed Web of Science ®Google Scholar
• Thomas O’Neil BM. Cystic fibrosis foundation patient registry 2019 annual data report. Bethesda, Maryland: ©2020 Cystic Fibrosis Foundation; 2020. Available from: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf. Accessed June 15, 2021.
   Google Scholar
• Huang YJ, LiPuma JJ. The microbiome in cystic fibrosis. Clin Chest Med. 2016;37(1):59–67. doi:10.1016/j.ccm.2015.10.00326857768
   PubMed Web of Science ®Google Scholar
• Aaron SD. Changes in the cystic fibrosis airway microbiome after lung transplant: the more things change, the more they stay the same. Annals ATS. 2016;13(12):2109–2110. doi:10.1513/AnnalsATS.201609-700ED
   Web of Science ®Google Scholar
• Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25(6):1340. doi:10.3390/molecules25061340
   PubMed Web of Science ®Google Scholar
• Rocha GA, Lima DF, Rodrigues ER, et al. Species distribution, sequence types and antimicrobial resistance of Acinetobacter spp. from cystic fibrosis patients. Epidemiol Infect. 2018;146(4):524–530. doi:10.1017/S095026881700284929283077
   PubMed Web of Science ®Google Scholar
• Vermeulen F, Proesmans M, Vermaelen M, Boon M, De Boeck K. Isolation of Enterobacteriaceae in airway samples is associated with worse outcome in preschool children with cystic fibrosis. J Cystic Fibrosis. 2020;19(3):365–369. doi:10.1016/j.jcf.2019.10.019
   Web of Science ®Google Scholar
• Egan T. Long term results of lung transplantation for cystic fibrosis. Eur J Cardio Thorac Surg. 2002;22(4):602–609. doi:10.1016/S1010-7940(02)00376-7
   PubMed Web of Science ®Google Scholar
• Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect. 2004;56(4):277–282. doi:10.1016/j.jhin.2004.01.00315066737
   PubMed Web of Science ®Google Scholar
• Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transpl. 2007;26(9):890–897. doi:10.1016/j.healun.2007.07.002
   PubMed Web of Science ®Google Scholar
• Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64:10. doi:10.1128/AAC.00397-20
   Web of Science ®Google Scholar
• Pollini S, Mugnaioli C, Dolce D, et al. Chronic infection sustained by a Pseudomonas aeruginosa high-risk clone producing the VIM-1 metallo-β-lactamase in a cystic fibrosis patient after lung transplantation. J Cystic Fibrosis. 2018;17(4):470–474. doi:10.1016/j.jcf.2018.01.007
   Web of Science ®Google Scholar
• Carugati M, Piazza A, Peri AM, et al.; IFALT working group. Fatal respiratory infection due to ST308 VIM-1-producing Pseudomonas aeruginosa in a lung transplant recipient: case report and review of the literature. BMC Infect Dis. 2020;20(1):635. doi:10.1186/s12879-020-05338-332847524
   PubMed Web of Science ®Google Scholar
• Pouch SM, Patel G; the AST Infectious Diseases Community of Practice. Multidrug‐resistant gram‐negative bacterial infections in solid organ transplant recipients—guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9). doi:10.1111/ctr.13594
   Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31–51. doi:10.1007/s40265-013-0168-224352909
   PubMed Web of Science ®Google Scholar
• Arena F, Marchetti L, Henrici De Angelis L, et al. Ceftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation in a lung transplant recipient. Antimicrob Agents Chemother. 2019;63(3). doi:10.1128/AAC.02131-18
   Web of Science ®Google Scholar
• Puzniak L, Dillon R, Palmer T, Collings H, Enstone A. Real-world use of ceftolozane/tazobactam: a systematic literature review. Antimicrob Resist Infect Control. 2021;10(1):68. doi:10.1186/s13756-021-00933-833832545
   PubMed Web of Science ®Google Scholar
• Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations. Clin Infect Dis. 2019;68(3):519–524. doi:10.1093/cid/ciy57630020449
   PubMed Web of Science ®Google Scholar
• Pouch SM. New drugs for difficult bugs: management of multidrug-resistant gram-negative infections in solid organ transplant recipients. Curr Opin Organ Transplant. 2021. doi:10.1097/MOT.0000000000000890
   Web of Science ®Google Scholar
• Koutsokera A, Varughese RA, Sykes J, et al. Pre-transplant factors associated with mortality after lung transplantation in cystic fibrosis: a systematic review and meta-analysis. J Cystic Fibrosis. 2019;18(3):407–415. doi:10.1016/j.jcf.2018.10.013
   PubMed Web of Science ®Google Scholar
• Courtney JM, Dunbar KEA, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cystic Fibrosis. 2004;3(2):93–98. doi:10.1016/j.jcf.2004.01.005
   PubMedGoogle Scholar
• Snell G, Smibert O, Tullis E. Burkholderia in transplant: important to speciate and important to treat. In: Morris MI, Kotton CN, Wolfe C, editors. Emerging Transplant Infections. Springer International Publishing; 2020:1–19. doi:10.1007/978-3-030-01751-4_22-1
   Google Scholar
• Bartley BL, Gardner KJ, Spina S, et al. High-dose inhaled nitric oxide as adjunct therapy in cystic fibrosis targeting Burkholderia multivorans. Case Rep Pediatr. 2020;2020:1–6. doi:10.1155/2020/1536714
   Web of Science ®Google Scholar
• McCallin S, Brüssow H. Clinical trials of bacteriophage therapeutics. In: Harper DR, Abedon ST, Burrowes BH, McConville ML, editors. Bacteriophages. Springer International Publishing; 2021:1099–1127. doi:10.1007/978-3-319-41986-2_38
   Google Scholar
• Kamal F, Dennis JJ, Elliot MA. Burkholderia cepacia Complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity. Elliot MA, ed. Appl Environ Microbiol. 2015;81(3):1132–1138. doi:10.1128/AEM.02850-1425452284
   PubMed Web of Science ®Google Scholar
• Zeriouh M, Sabashnikov A, Patil NP, et al. Use of taurolidine in lung transplantation for cystic fibrosis and impact on bacterial colonization†. Eur J Cardio Thorac Surg. 2018;53(3):603–609. doi:10.1093/ejcts/ezx359
   Web of Science ®Google Scholar
• Adjemian J, Olivier KN, Prevots DR. Erratum: epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010–2014. Annals ATS. 2018;15(9):1114–1115. doi:10.1513/AnnalsATS.159erratum
   Google Scholar
• Piersimoni C. Nontuberculous mycobacteria infection in solid organ transplant recipients. Eur J Clin Microbiol Infect Dis. 2012;31(4):397–403. doi:10.1007/s10096-011-1329-421732201
   PubMed Web of Science ®Google Scholar
• Degiacomi S, Chiarelli R, Makarov P. Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients. IJMS. 2019;20(23):5868. doi:10.3390/ijms20235868
   Web of Science ®Google Scholar
• Vazirani J, Snell GI, Westall GP. Prolonged survival after lung transplantation in the absence of conventional immunosuppression. J Heart Lung Transpl. 2020;39(10):1159–1162. doi:10.1016/j.healun.2020.06.018
   Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1–e36. doi:10.1093/cid/ciaa24132628747
   PubMed Web of Science ®Google Scholar
• Weng Y-W, Huang C-K, Sy C-L, Wu K-S, Tsai H-C, Lee SS-J. Treatment for Mycobacterium abscessus complex–lung disease. J Formosan Med Assoc. 2020;119:S58–S66. doi:10.1016/j.jfma.2020.05.02832527504
   PubMed Web of Science ®Google Scholar
• Higuchi T, Oto T, Millar IL, Levvey BJ, Williams TJ, Snell GI. Preliminary report of the safety and efficacy of hyperbaric oxygen therapy for specific complications of lung transplantation. J Heart Lung Transpl. 2006;25(11):1302–1309. doi:10.1016/j.healun.2006.08.006
   Web of Science ®Google Scholar
• Tan S, Kasperbauer S. Nontuberculous mycobacteria. Semin Respir Crit Care Med. 2021;42(04):567–586. doi:10.1055/s-0041-173099734261181
   PubMed Web of Science ®Google Scholar
• Shirley M. Correction to: amikacin liposome inhalation suspension: a review in mycobacterium avium complex lung disease. Drugs. 2019;79(7):791. doi:10.1007/s40265-019-01111-230941606
   PubMed Web of Science ®Google Scholar
• Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium Complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559–1569. doi:10.1164/rccm.201807-1318OC30216086
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015;45(4):1177–1179. doi:10.1183/09031936.0016911425614169
   PubMed Web of Science ®Google Scholar
• Poon YK, La Hoz RM, Hynan LS, Sanders J, Monogue ML. Tedizolid vs linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients. Open Forum Infect Dis. 2021;8(4):ofab093. doi:10.1093/ofid/ofab09333884276
   PubMed Web of Science ®Google Scholar
• Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91(1):119–126. doi:10.1016/S0092-8674(01)80014-39335340
   PubMed Web of Science ®Google Scholar
• Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome: CMV in the allograft is associated with BOS. Am J Transpl. 2011;11(10):2190–2196. doi:10.1111/j.1600-6143.2011.03663.x
   PubMed Web of Science ®Google Scholar
• Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 1991;10(5 Pt 1):638–644; discussion 645–646.
   Web of Science ®Google Scholar
• van Delden C, Stampf S, Hirsch HH, et al. Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study. Clin Infect Dis. 2020;71(7):e159–e169. doi:10.1093/cid/ciz111331915816
   PubMed Web of Science ®Google Scholar
• Heliövaara E, Husain S, Martinu T, et al. Drug-resistant cytomegalovirus infection after lung transplantation: incidence, characteristics, and clinical outcomes. J Heart Lung Transplant. 2019;38(12):1268–1274. doi:10.1016/j.healun.2019.09.00531570289
   PubMed Web of Science ®Google Scholar
• Gagermeier JP, Rusinak JD, Lurain NS, et al. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis. 2014;16(6):941–950. doi:10.1111/tid.1231725491023
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–931. doi:10.1097/TP.000000000000219129596116
   PubMed Web of Science ®Google Scholar
• Wilkens H, Sester M. Treatment of cytomegalovirus infection with cidofovir and CMV immune globulin in a lung transplant recipient. Case Rep Transplant. 2016;2016:4560745. doi:10.1155/2016/456074526885432
   PubMedGoogle Scholar
• Schulz U, Solidoro P, Müller V, et al. CMV immunoglobulins for the treatment of CMV infections in thoracic transplant recipients. Transplantation. 2016;100(Suppl 3):S5–10. doi:10.1097/TP.000000000000109726900992
   PubMed Web of Science ®Google Scholar
• Veit T, Munker D, Kauke T, et al. Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipients. Transplantation. 2020;104(2):410–414. doi:10.1097/TP.000000000000288631385924
   PubMed Web of Science ®Google Scholar
• Smith C, Beagley L, Rehan S, et al. Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial. Clin Infect Dis. 2019;68(4):632–640. doi:10.1093/cid/ciy54929982441
   PubMed Web of Science ®Google Scholar
• Kuri A, Jacobs BM, Vickaryous N, et al. Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 2020;20(1):912. doi:10.1186/s12889-020-09049-x32532296
   PubMed Web of Science ®Google Scholar
• Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998;338(20):1413–1421. doi:10.1056/NEJM1998051433820039580648
   PubMed Web of Science ®Google Scholar
• Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–1227. doi:10.1038/sj.bjc.660121914520450
   PubMed Web of Science ®Google Scholar
• Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant. 2011;25(4):E430–436. doi:10.1111/j.1399-0012.2011.01464.x21518001
   PubMed Web of Science ®Google Scholar
• Lowery EM, Adams W, Grim SA, Clark NM, Edwards L, Layden JE. Increased risk of PTLD in lung transplant recipients with cystic fibrosis. J Cyst Fibros. 2017;16(6):727–734. doi:10.1016/j.jcf.2017.03.01328456611
   PubMed Web of Science ®Google Scholar
• AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S. The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am J Transplant. 2017;17(3):770–781. doi:10.1111/ajt.1402027545492
   PubMed Web of Science ®Google Scholar
• Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). Am J Transplant. 2011;11(2):336–347. doi:10.1111/j.1600-6143.2010.03387.x21219573
   PubMed Web of Science ®Google Scholar
• Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010;149(5):693–705. doi:10.1111/j.1365-2141.2010.08160.x20408848
   PubMed Web of Science ®Google Scholar
• Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007;86(8):599–607. doi:10.1007/s00277-007-0298-217522862
   PubMed Web of Science ®Google Scholar
• Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35(5):536–543. doi:10.1200/JCO.2016.69.356427992268
   PubMed Web of Science ®Google Scholar
• Viswesh V, Yost SE, Kaplan B. The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: a systematic review. Transplant Rev (Orlando). 2015;29(3):175–180. doi:10.1016/j.trre.2015.02.00425736693
   PubMedGoogle Scholar
• Dufek S, Haitel A, Müller-Sacherer T, Aufricht C. Duct Bellini carcinoma in association with BK virus nephropathy after lung transplantation. J Heart Lung Transplant. 2013;32(3):378–379. doi:10.1016/j.healun.2012.11.03323321158
   PubMed Web of Science ®Google Scholar
• Kuppachi S, Holanda D, Eberlein M, et al. An unexpected surge in plasma BKPyV viral load heralds the development of BKPyV-associated metastatic bladder cancer in a lung transplant recipient with BKPyV nephropathy. Am J Transplant. 2017;17(3):813–818. doi:10.1111/ajt.1405727647675
   PubMed Web of Science ®Google Scholar
• Moscarelli L, Caroti L, Antognoli G, et al. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transplant. 2013;27(4):546–554. doi:10.1111/ctr.1215123758330
   PubMed Web of Science ®Google Scholar
• Wojciechowski D, Chandran S, Webber A, Hirose R, Vincenti F. Mycophenolate mofetil withdrawal with conversion to everolimus to treat BK virus infection in kidney transplant recipients. Transplant Proc. 2017;49(8):1773–1778. doi:10.1016/j.transproceed.2017.06.03028923623
   PubMed Web of Science ®Google Scholar
• Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17(11):658–665. doi:10.1007/s00147-004-0779-315616809
   PubMed Web of Science ®Google Scholar
• Ishii K, Yamamoto F, Homma S, et al. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review. BMC Neurol. 2019;19(1):263. doi:10.1186/s12883-019-1493-131672142
   PubMed Web of Science ®Google Scholar
• Crowhurst T, Koszyca B, Holmes M, Holmes-Liew C-L. Progressive multifocal leukoencephalopathy in a lung transplant recipient presenting with memory impairment: case report and literature review. Transpl Infect Dis. 2020;22(3):e13293. doi:10.1111/tid.1329332291834
   PubMed Web of Science ®Google Scholar
• Renner S, Nachbaur E, Jaksch P, Dehlink E. Update on respiratory fungal infections in cystic fibrosis lung disease and after lung transplantation. JoF. 2020;6(4):381. doi:10.3390/jof604038133371198
   PubMed Web of Science ®Google Scholar
• Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transpl. 2003;22(3):258–266. doi:10.1016/S1053-2498(02)00477-1
   Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant‐Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–1111. doi:10.1086/65126220218876
   PubMed Web of Science ®Google Scholar
• Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev. 2008;22(2):89–104. doi:10.1016/j.trre.2007.12.007
   Google Scholar
• Li J, Nguyen C, Garcia-Diaz J. Role of new antifungal agents in the treatment of invasive fungal infections in transplant recipients: isavuconazole and new posaconazole formulations. JoF. 2015;1(3):345–366. doi:10.3390/jof103034529376915
   PubMedGoogle Scholar
• Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Myco. 2016;54(8):781–786. doi:10.1093/mmy/myw035
   PubMed Web of Science ®Google Scholar
• Al Shakirchi M, Klingspor L, Bergman P, Hjelte L, de Monestrol I. A 16-year retrospective study on fungal prevalence and diversity in patients with cystic fibrosis: candida dubliniensis was associated with a decline in lung function. Int J Infect Dis. 2020;96:663–670. doi:10.1016/j.ijid.2020.05.06332450290
   PubMed Web of Science ®Google Scholar
• Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients1. Transplantation. 2000;69(11):2360–2366. doi:10.1097/00007890-200006150-0002510868641
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–2029. doi:10.1056/NEJMoa02158512490683
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472–2482. doi:10.1056/NEJMoa06690617568028
   PubMed Web of Science ®Google Scholar
• Vazirani J, Westall GP, Snell GI, Morrissey CO. Scedosporium apiospermum and Lomentospora prolificans in lung transplant patients – a single center experience over 24 years. Transpl Infect Dis. 2021;23(3). doi:10.1111/tid.13546
   Web of Science ®Google Scholar
• Denton EJ, Smibert O, Gooi J, et al. Invasive Scedosporium sternal osteomyelitis following lung transplant: cured. Med Mycol Case Rep. 2016;12:14–16. doi:10.1016/j.mmcr.2016.07.00127595059
   PubMed Web of Science ®Google Scholar
• Husain S, Muñoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40(1):89–99. doi:10.1086/42644515614697
   PubMed Web of Science ®Google Scholar
• Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52(5):1743–1750. doi:10.1128/AAC.01388-0718212110
   PubMed Web of Science ®Google Scholar
• Seidel D, Meißner A, Lackner M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol. 2019;45(1):1–21. doi:10.1080/1040841X.2018.151436630628529
   PubMed Web of Science ®Google Scholar
• Jenks JD, Seidel D, Cornely OA, et al. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: analysis of patients in the FungiScope® registry. Mycoses. 2020;63(5):437–442. doi:10.1111/myc.1306732080902
   PubMed Web of Science ®Google Scholar
• Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation-a world-wide survey: world-wide survey of antifungal prophylaxis. Am J Transpl. 2011;11(2):361–366. doi:10.1111/j.1600-6143.2010.03375.x
   Web of Science ®Google Scholar
• Pilarczyk K, Haake N, Heckmann J, et al. Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies. Clin Transplant. 2016;30(12):1522–1531. doi:10.1111/ctr.1285427653443
   PubMed Web of Science ®Google Scholar
• Pennington KM, Baqir M, Erwin PJ, Razonable RR, Murad MH, Kennedy CC. Antifungal prophylaxis in lung transplant recipients: a systematic review and meta‐analysis. Transpl Infect Dis. 2020;22(4). doi:10.1111/tid.13333
   Web of Science ®Google Scholar
• Bhaskaran A, Mumtaz K, Husain S. Anti-aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep. 2013;15(6):514–525. doi:10.1007/s11908-013-0380-y24173585
   PubMed Web of Science ®Google Scholar
• Husain S, Bhaskaran A, Rotstein C, et al. A strategy for prevention of fungal infections in lung transplantation: role of bronchoalveolar lavage fluid galactomannan and fungal culture. J Heart Lung Transpl. 2018;37(7):886–894. doi:10.1016/j.healun.2018.02.006
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Review of the novel investigational antifungal olorofim. JoF. 2020;6(3):122. doi:10.3390/jof6030122
   Web of Science ®Google Scholar
• Tio SH, Thursky K, Ng G, Rex JH, Carney D, Slavin M. Olorofim for a case of severe disseminated Lomentospora prolificans infections. In Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France. April 18 2020.
   Google Scholar
• Chen S, Rai NJ, Cunneen S, et al. A case of Lomentospora prolificans treated with the novel antifungal olorofim. In Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France. 2020:abstr. 2585.
   Google Scholar
• Morrissey CO, Garlick J, Gaffney N, Harvey E, Rex J. Long-term use of olorofim in the treatment of scedosporium apiospermum chest wall infection. In Proceedings of the 31st European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria. 2021:abstr.2641.
   Google Scholar
• Zhao M, Lepak AJ, Marchillo K, et al. APX001 pharmacokinetic/pharmacodynamic target determination against aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2019;63:e02372–18. doi:10.1128/AAC.02372-1830670426
   PubMed Web of Science ®Google Scholar